This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Researchers To Present Data On Soliris® (eculizumab) As A Treatment For Patients With AHUS And STEC-HUS At ASN Annual Meeting

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data from clinical studies of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) and Shiga toxin-producing E. Coli hemolytic uremic syndrome (STEC-HUS), two severe and life-threatening ultra-rare disorders caused by uncontrolled complement activation, at the annual meeting of the American Society of Nephrology (ASN). Abstracts summarizing these presentations were published today on the ASN website and can be accessed using the links below. The ASN annual meeting will be held October 30 – November 4, 2012 in San Diego, California.

Soliris is approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is also approved in the United States as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a debilitating, ultra-rare, life-threatening and chronic genetic disorder characterized by complement-mediated thrombotic microangiopathy (blood clots in small vessels). Soliris is not indicated for the treatment of patients with Shiga toxin-producing E. Coli hemolytic uremic syndrome (STEC-HUS).

Soliris and aHUS

The following abstract will be presented in a poster presentation on Thursday, November 1, 2012 from 10:00 a.m. – 12:00 p.m., Pacific Daylight Time (PDT):

Abstract TH-PO442: “Eculizumab Is Effective in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Regardless of Underlying Genetic Mutations or Complement Factor H (CFH) Auto-Antibodies,” Goodship, et al.

Accessible at:

The following abstract will be presented in a poster session on Saturday, November 3, 2012 from 10:00 a.m. – 12:00 p.m., PDT:

Abstract SA-PO1039: “Eculizumab Therapy in an Atypical Hemolytic Uremic Syndrome (aHUS) Patient with Long-Term Renal Failure and Posterior Reversible Encephalopathy Syndrome (PRES),” Povey, et al.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs